RxDoctor Payments Data

Ian Elliot, MD

Endocrinology, Diabetes & Metabolism · Toledo, OHNPI 1649277328

Payments from drug & device makers

$3,899in general payments, 2019–2025

Across 76 payments — averaging $51.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Tandem Diabetes Care, Inc.$2K
  • Corcept Therapeutics$233
  • Johnson & Johnson$154
  • Amgen$135
  • Lilly USA, LLC$86
  • plus $216 from 8 others

What the payments were for

  • Speaking & faculty fees$1,47538%
  • Food & beverage$2,42462%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,899 in reported general payments places this provider in the 65th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$62,131
Medicare patients
380
Services billed
653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide120$172,860
ForteoTeriparatide22$127,492
TrulicityDulaglutide74$121,199
MounjaroTirzepatide44$70,153
HumatropeSomatropin12$43,032
JardianceEmpagliflozin36$40,436
JanuviaSitagliptin Phosphate27$38,488
GenotropinSomatropin17$34,911
FarxigaDapagliflozin Propanediol38$30,042
Tresiba Flextouch U-200Insulin Degludec38$30,033
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog62$29,803
Fiasp FlextouchInsulin Aspart (Niacinamide)35$29,536
Tresiba Flextouch U-100Insulin Degludec50$25,958
Testosterone54$25,833
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$20,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo, Trulicity, Mounjaro, Humatrope, Humalog$86$375,385204 claims
Novo NordiskOzempic$62$172,860120 claims
AstraZenecaFarxiga$11$30,04238 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$19,1911,671 claims
AmgenProlia$135$18,61911 claims
AbbVieSynthroid$19$8,990296 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →